Antipsychotic use is controversial in the management of adults with intellectual and developmental disabilities (IDD) because of limited evidence for efficacy without a comorbid psychiatric condition, and substantial concerns about adverse effects. There has been growing concern around the overuse of antipsychotic medications in this population, particularly because these individuals often have difficulties in providing informed consent to using medications and reporting of adverse effects due to impairments in communication, cognition and memory.
This study aimed to characterize antipsychotic use among Ontario adults with IDD and compare profiles of those with and without a documented psychiatric diagnosis.
Access the full article and associated resources: